Literature DB >> 23532442

Documentation of off-label use of biologics in Rheumatoid Arthritis.

Daniel E Furst1, Roy Fleischman, Joachim Kalden, Arthur Kavanaugh, Joachim Sieper, Philip Mease, Josef Smolen, Ferrie Breedveld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23532442     DOI： 10.1136/annrheumdis-2013-consensusapp

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012.

Authors:  Leah J McGrath; M Alan Brookhart
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Immediate neurological recovery following perispinal etanercept years after brain injury.

Authors:  Edward Tobinick; Helen Rodriguez-Romanacce; Arthur Levine; Tracey A Ignatowski; Robert N Spengler
Journal:  Clin Drug Investig       Date:  2014-05       Impact factor: 2.859

3.  Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.

Authors:  Tracey A Ignatowski; Robert N Spengler; Edward Tobinick
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences.

Authors:  Nikos Maniadakis; Emese Toth; Michael Schiff; Xuan Wang; Maria Nassim; Boglarka Szegvari; Irina Mountian; Jeffrey R Curtis
Journal:  Adv Ther       Date:  2018-08-04       Impact factor: 3.845
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.